13F Holdings
中文EN

MLSS MILESTONE SCIENTIFIC INC.

Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 855683 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.9%
TTM net income YoY46.6%
TTM EPS YoY55.6%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—

Margins

Gross margin70.9%
Operating margin-40.0%
Net margin-38.3%
FCF margin-16.0%
EBITDA margin-39.2%

Returns

ROE-114.7%
ROA-46.1%
ROIC (approx.)-165.6%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets47.3%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-27.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$8.97M$8.63M$9.83M$8.81M$10.30M
Cost of revenue$2.57M$2.20M$3.03M$3.91M$3.99M
Gross profit$6.41M$6.43M$6.79M$4.90M$6.31M
R&D expense$449,469$858,767$701,378$1.15M$878,210
SG&A expense$11.58M$12.30M$13.14M$12.51M$12.74M
Operating income-$5.70M-$6.76M-$7.11M-$8.83M-$7.38M
Pretax income-$5.72M-$4.71M-$6.98M-$8.77M-$7.12M
Income tax——$0$0$333
Net income-$5.72M-$4.71M-$6.93M-$8.71M-$6.82M
EBITDA-$5.62M-$6.72M-$7.04M-$8.76M-$7.30M
EPS (basic)-0.07-0.06-0.10-0.12-0.10
EPS (diluted)-0.07-0.06——-0.10
Weighted avg. shares (diluted)82.06M79.79M——68.83M
Banking
Net interest income—$60,265$125,527$54,607-$16,360
Balance sheet
Cash & equivalents$1.11M$3.26M$2.98M$8.72M$14.76M
Short-term investments—$0$2.98M$0$14.80M
Receivables—$475,376$312,664$693,717$943,272
Inventory$3.78M$3.71M$2.64M$1.79M$1.54M
Current assets$7.48M$9.29M$10.79M$12.97M$18.93M
PP&E, net$19,193$12,921$10,024$18,146$23,713
Intangibles$79,063$148,404$178,636$227,956$277,619
Total assets$7.81M$9.80M$11.37M$13.70M$19.81M
Current liabilities$3.94M$3.74M$3.08M$3.30M$3.10M
Total liabilities$4.80M$3.96M$3.36M$3.70M$3.59M
Shareholders' equity$3.01M$5.83M$8.01M$10.23M$16.37M
Shares outstanding80.45M78.01M75.85M69.27M68.12M
Cash flow statement
Operating cash flow-$2.92M-$2.92M-$5.33M-$6.03M-$4.03M
Capital expenditure$15,124$10,124—$8,527$15,189
Free cash flow-$2.93M-$2.93M—-$6.04M-$4.05M
Investing cash flow-$15,124$2.97M-$2.97M-$8,527-$15,189
Financing cash flow$786,335$233,771$2.56M-$8,544$4.59M
Depreciation & amortization$78,195$37,448$61,912$63,755$73,836
Stock-based compensation$952,716$1.35M$1.47M$1.50M$790,915

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.